The prediction performances of CD40 are comparable to CD8 in ≥50% melanoma cohorts and one gastric cancer cohort, where both biomarkers exhibited an AUC > 0.7, predicting a strong likelihood of positive response to immunotherapy. Here, CD40 is linked to melanoma.